AEON Biopharma, Inc. Class A Common Stock (AEON)

AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, has announced the closing of its firm commitment underwritten public offering. AEON secured approximately $20.0 million in gross proceeds from the offering, of which it intends to use the net, together with its existing cash, for general corporate purposes and working capital. As detailed in the announcement, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or warrants to cover over-allotments, if any. On Jan. 7, Aegis exercised its over-allotment option with respect to 6,000,000 Series A Warrants and 6,000,000 Series B Warrants. Aegis acted as the sole book-running manager for the offering.